The U.S. Food and Drug Administration (FDA) has issued emergency use authorizations (EUA) for three monoclonal antibody therapeutics for treatment of early mild-to-moderate COVID-19 in high-risk patients.
Please note: Due to the presence of the Omicron variant and consistent with federal guidance, two monoclonal antibody (mAb) therapies, bamlanivimab/etesevimab and casirivimab/imdevimab, should no longer be used at this time.
The FDA has approved the use of one intravenous antiviral therapeutic for the treatment of early mild-to-moderate COVID-19 in high-risk patients.
The FDA has also issued EUAs for two oral antiviral therapeutics for treatment of early mild-to-moderate COVID-19 in high-risk patients.
Use of monoclonal antibodies or antiviral medications is not a substitute for vaccination against COVID-19. Everyone is still encouraged to get vaccinated as soon as they can, whether it is a first, second or booster dose.
- DPH Guidance, January 12, 2022: Use of Therapeutics for Treatment of COVID-19
- This guidance replaces guidance issued by the Department on December 23, 2021
- DPH Guidance, December 16: COVID-19 Monoclonal Antibody (mAb) Therapy Checklist for Providers
- DPH Guidance, December 16, 2021:Allocation of COVID-19 Monoclonal Antibody Therapeutics to Health Care Providers
Anti-SARS-CoV2 monoclonal antibodies and oral antivirals are available through state-funded sites located across the Commonwealth and managed by Gothams. These state-funded infusion sites include Athol, Everett, Fall River, Holyoke, Lowell, Pittsfield, Plymouth.
Any provider can refer patients who meet treatment criteria to these sites by submitting Gotham’s Provider Referral Form. Prior to referring patients, providers are strongly urged to consider the currently constrained supply of these therapeutics and refer those patients at the highest risk of developing severe COVID-19.
Download: Referral Form for monoclonal antibody and antiviral therapies.
Transportation to a treatment site should NOT be a barrier to care for patients diagnosed with COVID-19. Gothams will work with your patient to arrange for transportation to and from the treatment site closest to their home. There is no cost to the patient for this transportation.
Additionally, hospitals and other healthcare providers throughout Massachusetts serve as sites for distribution of COVID-19 therapeutics and will administer monoclonal antibodies and remdesivir and dispense oral antiviral therapy as supplies are available. The COVID-19 Therapeutics Locator can be used to locate sites offering monoclonal antibodies and antiviral therapies. For referrals to hospital sites, providers should use the contact number for the site listed on the site in locator map. Patients or their representative should follow the instructions provided by the healthcare provider as to how to receive the dispensed medication at the COVID-19 therapeutics site.
COVID-19 Therapeutics Locator
Oral antiviral therapy will also be available through prescription requests and distributed through community health centers (CHC) in areas with a high burden of COVID-19. For patients who are cared for through the CHC, oral antivirals will be prescribed by CHC clinicians and filled through the CHC pharmacy.
As oral antiviral therapies become more available, the number of sites dispensing the medication will increase.